A Phase 1 interventional study of Lumateperone 42 mg and Lumateperone 28 mg in Schizophrenia and Pediatric, sponsored by Intra-Cellular Therapies, Inc.. Completed at 3 sites in United States. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-11-12.
Sponsored by Intra-Cellular Therapies, Inc. (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing lumateperone in Schizophrenia — 3 open to participants now, 3 under way, 2 of them phase 3. lumateperone · Schizophrenia.
Among the 12 studies testing lumateperone in Schizophrenia, this one is the 10th largest by enrollment, is one of 2 that started in 2021, is one of 3 in phase 1, and was the 7th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →3 of the 12 studies testing lumateperone in Schizophrenia are open now, in 3 countries. Recruiting first, the newest first:
Louisiana State University Health Sciences Center Shreveport · Sites in United States
Ages 18–65
University of Massachusetts, Worcester · Sites in United States
Ages 18–65
Intra-Cellular Therapies, Inc. · Sites in United States, Colombia, Serbia
Ages 5–17
By country, each count listing its studies:
lumateperone: first FDA approval 2019 (CAPLYTA). What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 13 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, lumateperone is the treatment under test here. Read study by study →
12 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 66 across the 12 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 12 have an industry lead sponsor. The 4 most frequent:
This study is registered under Intra-Cellular Therapies, Inc., one of the names counted as Johnson & Johnson. Under that name alone:
Intra-Cellular Therapies, Inc. is the lead sponsor of 41 studies on the registry; 12 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 11 (46%) have results posted.
206 studies in Schizophrenia by Johnson & Johnson: 2 open now, 2 under way, 1 of them phase 3. Of 203 finished, 57 (28%) have results posted.
Among the 206 studies in Schizophrenia by Johnson & Johnson, this one is the 157th largest by enrollment of the 176 interventional ones that give a count, is one of 3 that started in 2021, is one of 42 in phase 1, and was the 201st registered.
Johnson & Johnson’s Schizophrenia studies by the year they started, since 1996.
2 of the studies testing lumateperone in Schizophrenia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06482554Phase 3Louisiana State University Health Sciences Center ShreveportLumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. | 2026-12 |
| NCT06174116University of Massachusetts, WorcesterMetabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies testing lumateperone in Schizophrenia, from their registry updates:
Among Johnson & Johnson’s 206 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
Study ITI-007-020 is a Phase 1b, multicenter, open-label study to evaluate the safety, tolerability, and PK of lumateperone as treatment for adolescent patients with schizophrenia or schizoaffective disorder.
Main Inclusion Criteria:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Lumateperone 42 mg
Drug: Lumateperone 28 mg
Lumateperone 42 mg, oral administration
Lumateperone 28 mg, oral administration
Pharmacokinetics: Cmax
Maximum plasma concentration of lumateperone
Time frame: Day 1 and Day 5
Pharmacokinetics: Tmax
Time of maximum concentration of lumateperone in plasma
Time frame: Day 1 and Day 5
Pharmacokinetics: AUC0-t
Area under the plasma concentration time curve from time zero to the last measurable of concentration of lumateperone
Time frame: 0 to 24 hours post-dose on Day 1 and Day 5
Pharmacokinetics: AUC0-tau
Area under the plasma lumateperone concentration time curve from time zero to the end of dosing (tau)
Time frame: 0 to 24 hours post-dose on Day 1 and Day 5
Pharmacokinetics: t1/2
Terminal elimination half-life of lumateperone
Time frame: Day 1 and Day 5
Pharmacokinetics: CL/F
Apparent oral clearance of lumateperone
Time frame: Day 1 and Day 5
Percentage of Subjects With Treatment-emergent Adverse Events
Time frame: up to 30 days after last dose, up to a total of 35 days
Change From Baseline in Systolic and Diastolic Blood Pressure
Time frame: Baseline and Day 6
Change From Baseline in ECG QT Interval
QTcF
Time frame: Baseline and Day 6
Change From Baseline in Hemoglobin
Time frame: Baseline and Day 6
Change From Baseline in White Blood Cell Count
Time frame: Baseline and Day 6
Change From Baseline in Aspartate Aminotransferase
Time frame: Baseline and Day 6
Change From Baseline in Alanine Aminotransferase
Time frame: Baseline and Day 6
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS)
AIMS is a measure of facial and oral movements, extremity movements and trunk movements. The AIMS total score is reported based on 7 items (items 1 through 7). Each item is rated on a scale from none (0) to severe (4). The AIMS total score ranges from 0 to 28. Higher values of total AIMS score indicate increased severity in abnormal movement.
Time frame: Baseline and Day 6
| Milestone | Lumateperone 42 mg Once Daily for 5 Days |
|---|---|
| Started | 26 |
| Completed | 21 |
| Not completed | 5 |
Maximum plasma concentration of lumateperone
| ng/mL | Lumateperone 42 mg Once Daily for 5 Days |
|---|---|
| Day 1 | 19.12 ± 11.21 |
| Day 5 | 23.22 ± 12.60 |
Time of maximum concentration of lumateperone in plasma
| h | Lumateperone 42 mg Once Daily for 5 Days |
|---|---|
| Day 1 | 1.000 (0.25 to 6.00) |
| Day 5 | 1.000 (0.50 to 4.00) |
Area under the plasma concentration time curve from time zero to the last measurable of concentration of lumateperone
| h*ng/mL | Lumateperone 42 mg Once Daily for 5 Days |
|---|---|
| Day 1 | 43.612 ± 21.404 |
| Day 5 | 54.975 ± 26.992 |
Area under the plasma lumateperone concentration time curve from time zero to the end of dosing (tau)
| h*ng/mL | Lumateperone 42 mg Once Daily for 5 Days |
|---|---|
| Day 1 | 48.158 ± 20.899 |
| Day 5 | 58.437 ± 27.792 |
Terminal elimination half-life of lumateperone
| h | Lumateperone 42 mg Once Daily for 5 Days |
|---|---|
| Day 1 | 2.208 ± 0.6162 |
| Day 5 | 2.681 ± 1.092 |
Apparent oral clearance of lumateperone
| L/h | Lumateperone 42 mg Once Daily for 5 Days |
|---|---|
| Day 1 | 3062.0 ± 1292.0 |
| Day 5 | 947.14 ± 595.34 |
| Participants | Lumateperone 42 mg Once Daily for 5 Days |
|---|---|
| Percentage of Subjects With Treatment-emergent Adverse Events | 16 |
| mmHg | Lumateperone 42 mg Once Daily for 5 Days |
|---|---|
| Supine Systolic Blood Pressure | 0.7 ± 10.74 |
| Diastolic Systolic Blood Pressure | -0.5 ± 6.64 |
QTcF
| msec | Lumateperone 42 mg Once Daily for 5 Days |
|---|---|
| Change From Baseline in ECG QT Interval | -3.4 ± 15.19 |
| g/dL | Lumateperone 42 mg Once Daily for 5 Days |
|---|---|
| Change From Baseline in Hemoglobin | -0.50 ± 0.959 |
| cells*10^9/L | Lumateperone 42 mg Once Daily for 5 Days |
|---|---|
| Change From Baseline in White Blood Cell Count | -0.24 ± 1.173 |
| U/L | Lumateperone 42 mg Once Daily for 5 Days |
|---|---|
| Change From Baseline in Aspartate Aminotransferase | -4.0 ± 2.78 |
| U/L | Lumateperone 42 mg Once Daily for 5 Days |
|---|---|
| Change From Baseline in Alanine Aminotransferase | -3.2 ± 2.81 |
AIMS is a measure of facial and oral movements, extremity movements and trunk movements. The AIMS total score is reported based on 7 items (items 1 through 7). Each item is rated on a scale from none (0) to severe (4). The AIMS total score ranges from 0 to 28. Higher values of total AIMS score indicate increased severity in abnormal movement.
| score on a scale | Lumateperone 42 mg Once Daily for 5 Days |
|---|---|
| Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) | 0.0 ± 0.00 |
Collected over up to 30 days after last dose, up to a total of 35 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lumateperone 42 mg Once Daily for 5 Days | 0/26 (0%) | 0/26 (0%) | 16/26 (61.5%) |
| Event | Lumateperone 42 mg Once Daily for 5 Days |
|---|---|
| NauseaGastrointestinal disorders | 7/26 |
| HeadacheNervous system disorders | 6/26 |
| VomitingGastrointestinal disorders | 5/26 |
| DizzinessNervous system disorders | 4/26 |
| SomnolenceNervous system disorders | 4/26 |
| Orthostatic hypotensionVascular disorders | 3/26 |
| Age, Continuous(years) | Lumateperone 42 mg Once Daily for 5 Days |
|---|---|
| Mean | 15.2 ± 1.41 |
| Sex: Female, Male(Participants) | Lumateperone 42 mg Once Daily for 5 Days |
|---|---|
| Female | 11 |
| Male | 15 |
| Ethnicity (NIH/OMB)(Participants) | Lumateperone 42 mg Once Daily for 5 Days |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 26 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Lumateperone 42 mg Once Daily for 5 Days |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 26 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2021 to primary completion in Jul 2022, 16 months.
Results were first posted in Nov 2025, 3 years 3 months after primary completion.
Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 16 months is above that.
Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lumateperone
Intra-Cellular Therapies, Inc. →